IONIS-FB-LRx, also known as RG6299, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of complement factor B (FB) and the alternative complement pathway. Genetic association studies have shown that overaction of the alternative complement pathway has been associated with the development of several complement-mediated diseases, including geographic atrophy (GA), secondary to age-related macular degeneration (AMD).
About Age-related Macular Degeneration
Age-related Macular Degeneration (AMD) is the leading cause of central vision loss in developed countries. GA is an advanced form of AMD.
Safety and efficacy have not been evaluated by any regulatory authorities for the indications described.